SCNI Scinai Immunotherapeutics Ltd. - American Depositary Shares

NASDAQ · Biotechnology · View on SEC EDGAR ↗
$0.26
Price · Aug 19, 2026
Fundamentals as of May 15, 2023
52W Range
$0–$2
3% of range
Analyst Rating
BUY
7 analysts
Price Target
—
P/E (TTM)
—
ROE
—
Net Profit Margin
—

SCNI Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$0.26
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$0 – $2

SCNI Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income —
EPS —
2-point trend, +50.0%
2021-12-31 → 2022-12-31
Free Cash Flow —
2022-12-31 → 2022-12-31
Margins —

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
SCNI
Peer Median

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
SCNI
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
SCNI
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
SCNI
Peer Median

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
SCNI
Peer Median

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
SCNI
Peer Median

SCNI Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 7 analysts
  • Strong Buy 2 28.6%
  • Buy 4 57.1%
  • Hold 1 14.3%
  • Sell 0 0.0%
  • Strong Sell 0 0.0%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
3.6%
Period EPS Actual EPS Est Surprise
Dec. 31, 2023 $-4.70 $-6.32 1.6%
Sept. 30, 2023 $8.00 $-10.10 18.1%
June 30, 2023 $-11.10 $-9.28 -1.8%
March 31, 2023 $-10.90 $-7.45 -3.5%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
SCNI — — — — — —
CLGN — — — — — —
GLMD — — — — — —
SLXN — 0.2 — — — —
URGN $1.13B — 21.4% -139.8% 154.4% 88.7%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 10
Annual Income Statement data for SCNI
Metric Trend 20222021
R&D Expense 2-point trend, +77.4% $6M $3M
SG&A Expense 2-point trend, -30.5% $5M $8M
Operating Income 2-point trend, -1.8% $-11M $-11M
Other Non-op 2-point trend, +928.2% $5M $496.0K
Net Income 2-point trend, +29.4% $-6M $-8M
EPS (Basic) 2-point trend, +50.0% $-0.01 $-0.02
EPS (Diluted) 2-point trend, +50.0% $-0.01 $-0.02
Shares (Basic) 2-point trend, +33.6% 754,076,407 564,575,967
Shares (Diluted) 2-point trend, +33.6% 754,076,407 564,575,967
EBITDA $-10M ·
Balance Sheet 18
Annual Balance Sheet data for SCNI
Metric Trend 20222021
Cash & Equivalents 2-point trend, -19.0% $14M $17M
Prepaid Expense 2-point trend, -32.0% $155.0K $228.0K
Current Assets 2-point trend, -19.5% $14M $18M
PP&E (Net) 2-point trend, -9.2% $11M $12M
PP&E (Gross) 2-point trend, -5.9% $14M $15M
Accum. Depreciation 2-point trend, +13.6% $2M $2M
Total Assets 2-point trend, -15.5% $27M $32M
Accrued Liabilities 2-point trend, +109.4% $756.0K $361.0K
Short-term Debt 2-point trend, +1.9% $382.0K $375.0K
Current Liabilities 2-point trend, -4.3% $2M $2M
Capital Leases 2-point trend, -25.4% $1M $1M
Total Debt $382.0K ·
Paid-in Capital 2-point trend, +2.7% $116M $113M
Retained Earnings 2-point trend, -5.3% $-116M $-110M
AOCI 2-point trend, +2.3% $-2M $-2M
Stockholders' Equity 2-point trend, -279.2% $-2M $982.0K
Liabilities + Equity 2-point trend, -15.5% $27M $32M
Shares Outstanding 2-point trend, +33.9% 989,290,784 739,048,544
Cash Flow 9
Annual Cash Flow data for SCNI
Metric Trend 20222021
D&A 2-point trend, +19.3% $562.0K $471.0K
Stock-based Comp 2-point trend, -41.9% $2M $3M
Other Non-cash $-4M ·
Operating Cash Flow 2-point trend, +2.2% $-7M $-7M
CapEx 2-point trend, +501.4% $836.0K $139.0K
Investing Cash Flow 2-point trend, -501.4% $-836.0K $-139.0K
Financing Cash Flow 2-point trend, -68.4% $7M $21M
Net Change in Cash 2-point trend, -122.9% $-3M $14M
Free Cash Flow $-8M ·
Profitability 2
Annual Profitability data for SCNI
Metric Trend 20222021
ROA -19.6% ·
ROE 442.1% ·
Liquidity & Solvency 3
Annual Liquidity & Solvency data for SCNI
Metric Trend 20222021
Current Ratio 6.1 ·
Quick Ratio 6.0 ·
Debt / Equity -0.2 ·
Per Share 4
Annual Per Share data for SCNI
Metric Trend 20222021
Book Value / Share $-0.00 ·
Cash Flow / Share $-0.01 ·
Cash / Share $0.01 ·
EPS (TTM) $-0.01 ·
Valuation (TTM) 10
Annual Valuation (TTM) data for SCNI
Metric Trend 20222021
Net Income TTM $-6M ·
Market Cap $29.28B ·
Enterprise Value $29.27B ·
P/E -2960.0 ·
P/B -16638.1 ·
P / Cash Flow -4030.7 ·
P / FCF -3614.7 ·
EV / EBITDA -2787.8 ·
EV / FCF -3613.0 ·
Earnings Yield -0.03% ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement
2022-12-312021-12-31
Net Income $-6M$-8M
Diluted EPS $-0.01$-0.02
Balance Sheet
2022-12-312021-12-31
Debt / Equity -0.2—
Current Ratio 6.1—
Quick Ratio 6.0—
Cash Flow
2022-12-312021-12-31
Free Cash Flow $-8M—

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 11 filers · $41K total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
7 (+7 vs prior Q) 0 (-3 vs prior Q) 2 (+2 vs prior Q) 1 (-1 vs prior Q) +163K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
CITADEL ADVISORS LLC $15,726 62,257 38.28% Shares
ARMISTICE CAPITAL, LLC $9,079 35,942 22.10% Shares
StoneX Group Inc. $4,563 13,092 11.11% Shares
XTX Topco Ltd $4,235 16,764 10.31% Shares
RHUMBLINE ADVISERS $3,417 13,513 8.32% Shares
CAPTRUST FINANCIAL ADVISORS $3,040 12,035 7.40% Shares
UBS Group AG $1,001 3,955 2.44% Shares
MORGAN STANLEY $15 58 0.04% Shares
Virtu Financial LLC $5 19,485 0.01% Shares
HRT FINANCIAL LP $3 12,088 0.01% Shares
ROYAL BANK OF CANADA $0 815 0.00% Shares

Company insiders 2 insiders · 1 officers · 2 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Amir Reichman Chief Executive Officer June 16, 2026 A 711,637,600 0 0 $0
Mark Germain Director June 16, 2026 A 120,000,000 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 2 positions

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Daniel E. Stone March 12, 2024 — Initial filing Passive investment SEC
Angels Investments in Hi Tech Ltd., Marius Nacht ×6 filings Dec. 27, 2022 — Initial filing — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.